<DOC>
	<DOCNO>NCT00483574</DOCNO>
	<brief_summary>This clinical trial evaluate safety two injection Menactra® Vaccine subject 9 month 12 month age second dose give concomitantly pediatric vaccine routinely administer US . Safety Objective : To describe safety profile two dos Menactra® Vaccine .</brief_summary>
	<brief_title>Study Safety Menactra® Vaccine When Administered With Other Pediatric Vaccines Healthy Toddlers</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Healthy , determine medical history physical examination Aged 9 month ( 249 305 day ) 12 month ( 365 400 day ) time enrollment The parent legal guardian sign dated Independent Ethics Committee ( IEC ) /Institutional Review Board ( IRB ) approve informed consent form . Exclusion Criteria : Serious acute chronic disease ( e.g. , cardiac , renal , metabolic , rheumatologic , psychiatric , hematologic , autoimmune disorder , diabetes , atopic condition , congenital defect , convulsion , encephalopathy , blood dyscrasia , leukemia , lymphomas type , malignant neoplasm affect bone marrow lymphatic system , acute untreated tuberculosis ) could interfere trial conduct completion . Known suspected impairment immunologic function . Acute medical illness within last 72 hour temperature ≥ 100.4ºF ( ≥ 38.0ºC ) time enrollment . History document invasive meningococcal disease previous meningococcal vaccination . Has receive fourth dose Prevnar , first dose measlesmumpsrubella ( MMR ) , varicella , hepatitis A ( HepA ) vaccine . Known human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C seropositivity report parent legal guardian . Received either immune globulin blood product within last 3 month . Suspected known hypersensitivity vaccine component . Thrombocytopenia bleed disorder contraindicate intramuscular ( IM ) vaccination . Parent legal guardian unable unwilling comply study procedure . Participation another interventional clinical trial 30 day precede enrollment , participation another clinical trial involve investigation drug , vaccine , medical procedure , medical device subject 's trial period . Diagnosed condition , opinion investigator , would pose health risk subject interfere evaluation vaccine . Received vaccine 30day period prior receipt study vaccine ( ) , schedule receive vaccination influenza vaccination hyposensitization therapy 30day period receipt study vaccine ( ) . Personal family history GuillainBarré Syndrome ( GBS ) . History seizure , include febrile seizure , neurologic disorder . Known hypersensitivity dry natural rubber latex . For subject schedule provide blood sample : Anticipated receive oral inject antibiotic therapy within 72 hour prior either study blood draw . Topical antibiotic antibiotic drop include exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Menactra® vaccine</keyword>
	<keyword>Meningococcal meningitis</keyword>
	<keyword>Measles</keyword>
	<keyword>Mumps</keyword>
	<keyword>Rubella</keyword>
	<keyword>Varicella virus</keyword>
	<keyword>Haemophilus influenzae type b</keyword>
	<keyword>Pneumococcal conjugate vaccine</keyword>
</DOC>